The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Proliferative Vitreoretinopathy

Interventions

DRUG: ADX-2191 (intravitreal methotrexate 0.8%)
OTHER: Standard surgical care procedure

Sponsor

Aldeyra Therapeutics, Inc.